Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Sanofi SA — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.17 (market cap $78.25B), while Sanofi SA trades at $40.51 (market cap $94.58B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.18%). Which is the better fit depends on your goals.
| NGG | SNY | |
|---|---|---|
Market Cap | $78.25B | $94.58B |
Volume | 1,070,031 | 3,988,460 |
Sector | Utilities | Health |
52-Week High | $93.93 | $52.34 |
52-Week Low | $73.54 | $39.12 |
Enterprise Value | $136.28B | $113.80B |
Dividend Yield | 4.14% | 6.18% |
Typical Hold Time | — | 94 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Sanofi (SNY) trades at $39.12, down 1.56% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with $46.72B revenue, 16.72% net margin, and reasonable valuation (P/E 21.71). Recent expansion of the Regeneron immunology alliance worth up to $8B signals growth potential beyond Dupixent, though 2026 forecasts indicate profit margin compression to 8.09%.
SNY presents a mixed outlook with strong current execution offset by future margin pressures. The bullish analyst consensus (44% Buy) and expanding immunology pipeline provide upside catalysts, while patent expirations and competitive threats pose medium-term risks. Cash flow volatility and debt levels require monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
